While combinatorial therapy with anti-VEGFR2 and anti–PD-L1 showed no induction of HEV in a GBM line, LTβR agonists were then trialed which induced HEVs and enhanced function of CD8+ T cells in GBM (157). Here, CD8A is linked to glioblastoma.